DYD. S. Ymankulov

D. S. Ymankulov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


D. S. Ymankulov has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Circular RNAs in the genomics and pathophysiology of cardiovascular diseases

    by K. A. Aitbaev, I. T. Murkamilov, V. V. Fomin, Zh. A. Murkamilova, Z. R. Rayimzhanov, Sh. Sh. Khakimov, J. I. Solizhonov, T. F. Yusupova, A. F. Yusupov, F. A. Yusupov, et al.

    Cardiovascular diseases (CVDs) remain the leading cause of global mortality, accounting for approximately one-third of all deaths. The growing prevalence of CVDs underscores the urgent need for novel diagnostic and therapeutic approaches. Circular RNAs (circRNAs), a class of single-stranded RNA molecules formed through back-splicing, have attracted considerable attention as potential biomarkers and therapeutic targets due to their unique characteristics. Unlike linear RNAs, circRNAs lack free 3′ and 5′ ends, making them highly resistant to exonuclease degradation and thereby markedly more stable, with a half-life approximately 2–5 times longer than that of linear RNAs. Their stability, tissue- and disease-specific expression patterns, evolutionary conservation, and responsiveness to pathological stimuli enable them to regulate key biological processes such as apoptosis, metabolism, and inflammation. Growing evidence suggests that circRNAs play a role in the pathogenesis of CVDs: circRNA expression levels differ between cardiac tissues of healthy individuals and those of patients with various CVDs; in arterial hypertension, circRNAs 0037909 and 0037911 are closely associated with elevated blood pressure; following myocardial infarction, circRNA FoxO3 exacerbates myocardial injury, whereas circ-Amotl1 attenuates apoptosis and reduces adverse remodeling; in myocardial hypertrophy, knockdown of circSlc8a1 decreases hypertrophy, while circRNA 000203 promotes it by modulating hypertrophic gene expression; in heart failure, an inverse correlation between MICRA levels and left ventricular ejection fraction has been identified, making MICRA a valuable early indicator of left ventricular dysfunction. This review provides a detailed analysis of circRNAs in CVDs, including their biogenesis, molecular mechanisms, and functional roles. It also evaluates their potential as diagnostic and prognostic biomarkers, and discusses therapeutic advances based on circRNAs (synthetic circRNA sponges) and low-molecular-weight drugs. However, despite these promising findings, numerous challenges remain unresolved, including tissue-specific delivery of circRNAs and control of their complex pleiotropic effects. Furthermore, most data on the role of circRNAs, particularly in CVDs, have been obtained from preclinical studies, often involving animal models or in vitro systems. Therefore, further validation through comprehensive preclinical research and well-designed clinical trials is essential. Successful future integration of circRNA-based tools into clinical practice could fundamentally transform CVD management, enabling earlier detection and more personalized treatment strategies.

  • Cardiac remodeling in chronic kidney disease associated with overweight and obesity

    by I.T. Murkamilov, K.A. Aitbaev, V.V. Fomin, Zh.A. Murkamilova, Z.R. Raimzhanov, Sh.SH. Khakimov, J.I. Solizhonov, Sh.E. Umurzakov, T.F. Yusupova, F.A. Yusupov, et al.

    Chronic kidney disease (CKD) is among the most prevalent non-communicable diseases globally and is recognized as a significant independent risk factor for cardiovascular complications (CVCs). The co-occurrence of overweight or obesity in patients with CKD exacerbates its role as a risk factor for CVCs. Objective. To evaluate the characteristics of left ventricular myocardial remodeling in chronic kidney disease patients with comorbid overweight or obesity, thereby assessing their potential role as a risk factor for cardiovascular complications. Materials and methods. A total of 485 patients with CKD (291 males and 194 females, with a mean age of 43.8 years) were examined. Patients were divided into two groups: CKD with overweight (n=298) and CKD with obesity (n=187). All participants underwent clinical assessments, laboratory tests, and echocardiographic examinations. Results. Patients in the CKD with overweight group exhibited lower hematocrit, red blood cell count, and glomerular filtration rate (GFR), as well as elevated potassium and creatinine levels, compared with those in the CKD with obesity group. Notably, C-reactive protein and glucose levels were markedly higher in the obesity group, whereas 24-hour proteinuria was more significant among overweight patients. Furthermore, the obese cohort had increased levels of total cholesterol and triglycerides. Echocardiographic evaluations revealed that left ventricular (LV) linear dimensions, myocardial mass, and left ventricular mass index (LVMI) were statistically significantly greater in the CKD with obesity group. Concentric LV remodeling was observed in 7.4% of patients with overweight and 5.9% of those with obesity. LV hypertrophy was identified in 51.7% of cases (47.3% in the CKD with overweight group and 58.8% in the CKD with obesity group). Eccentric LV hypertrophy was significantly more prevalent in both patient groups. Concentric hypertrophy was primarily observed in males in the CKD with obesity group, while eccentric hypertrophy was more common among females. A correlation was established between LVMI and the estimated GFR (r = –0.397). Conclusions. In patients with chronic kidney disease who are also classified as overweight, cardiac remodeling predominantly manifests as eccentric left ventricular hypertrophy. As body mass index increases, the incidence of concentric left ventricular hypertrophy also rises, particularly in male patients.

  • Systemic inflammation indices in chronic kidney disease: clinical significance and prognostic aspects

    by I. T. Murkamilov, K. A. Aitbaev, V. V. Fomin, Zh. A. Murkamilova, Z. R. Raimzhanov, Sh. Sh. Khakimov, J. I. Solizhonov, A. F. Yusupov, T. F. Yusupova, Z. F. Yusupova, et al.

    THE AIM: to investigate systemic inflammation indices and their association with risk factors for cardiovascular complications in patients with chronic kidney disease (CKD). PATIENTS AND METHODS. The study included 744 patients (454 men and 290 women) with CKD at predialysis stages; the mean age was 38.3 ± 13.0 years. Patients were divided into two groups: Group 1 – CKD with subnephrotic proteinuria (3.5 g/day, n = 266). All patients underwent peripheral blood and biochemical analyses with the calculation of systemic inflammation indices. RESULTS. In the group of patients with CKD and nephrotic proteinuria, leukocyte count, erythrocyte sedimentation rate, and plasma fibrinogen concentration were significantly higher than in patients with CKD and subnephrotic proteinuria. The platelet-to-lymphocyte ratio (PLR) was higher in patients with CKD and nephrotic proteinuria (8.92 ± 3.39 vs 8.12 ± 2.20, p = 0.001), whereas the lymphocyte-to-C-reactive protein ratio (L/C-RP) was higher in patients with CKD and subnephrotic proteinuria (0.833 [0.167; 2.583] vs 0.323 [0.156; 1.917], p = 0.031). Correlation analysis showed that leukocyte count was positively associated with heart rate (r = 0.264; p < 0.05), total cholesterol (r = 0.119; p < 0.05), and daily proteinuria (r = 0.097; p < 0.05); lymphocyte count correlated with diastolic blood pressure (r = 0.214; p < 0.05); PLR correlated with heart rate (r = 0.376; p < 0.05) and LDL cholesterol (r = 0.374; p < 0.05); LDL cholesterol correlated negatively with L/M (r = –0.253; p < 0.05) and M/L (r = 0.287; p < 0.05). Estimated glomerular filtration rate (eGFR) correlated with L/C-RP (r = 0.300; p < 0.05), systemic inflammation response index (SIRI, r = –0.079; p < 0.05), and neutrophil-to-lymphocyte ratio (NLR, r = –0.077; p < 0.05). A negatively correlation was found between L/C-RP and plasma fibrinogen levels (r = –0.267; p < 0.05). CONCLUSION. In patients with CKD and subnephrotic proteinuria, the lymphocyte-to-C-reactive protein ratio was higher, whereas the platelet-to-lymphocyte ratio was higher in those with CKD and nephrotic proteinuria. Systemic inflammation indices (L/CRP, SIRI, NLR) showed a strong correlation with glomerular filtration rate and were independently associated with the risk of renal function decline and cardiovascular complications.

  • Hyperuricemia and the cardio-reno-metabolic continuum in chronic kidney disease

    by I. T. Murkamilov, K. A. Aitbaev, V. V. Fomin, Zh. A. Murkamilova, Z. R. Raimzhanov, Sh. Sh. Khakimov, I. U. Abdurakhmanov, J. I. Solizhonov, T. F. Yusupova, Z. F. Yusupova, et al.

    Objective. To investigate the relationship between serum uric acid levels and echocardiographic (EchoCG) parameters, and to assess the association of hyperuricemia with cardiovascular and renal abnormalities in patients with chronic kidney disease (CKD). Material and methods. A cross-sectional retrospective study included clinical, instrumental, laboratory, and EchoCG data from 473 patients (307 men and 166 women) with a confi rmed diagnosis of CKD. The mean age of the study participants was 38.5 ± 12.7 years. Hyperuricemia was defi ned as serum uric acid ≥ 0.42 mmol/L in men and ≥ 0.36 mmol/L in women. Patients were divided into subgroups: CKD with hyperuricemia (n = 199) and CKD without hyperuricemia (n = 274). Results. Among all patients with CKD (n = 473), hyperuricemia was observed in 199 cases (42.0%). Compared with patients without hyperuricemia, those with CKD and hyperuricemia had signifi cantly higher mean age, body mass index, systolic and diastolic blood pressure the size of cardiac structures according to ECHOCG data and serum creatinine levels were statistically significantly higher. In contrast, hemoglobin concentration, red blood cell count, and estimated glomerular fi ltration rate (eGFR) were significantly lower. Signifi cant correlations of serum uric acid were found with systolic and diastolic blood pressure, eGFR, left atrial anteroposterior diameter, left ventricular end-systolic and end-diastolic diameter, interventricular septum thickness, posterior wall thickness of the left ventricle, left ventricular ejection fraction, and venous blood glucose. Conclusion. The study demonstrated a signifi cant contribution of hyperuricemia to alterations in the geometry of the left heart chambers and a decline in renal filtration function.

  • Cardiac and aortic lesions in nephrotic syndrome

    by I. T. Murkamilov, K. A. Aitbaev, V. V. Fomin, I. U. Abdurakhmanov, T. F. Yusupova, Z. F. Yusupova, F. A. Yusupov, J. I. Solizhonov, Yo. R. Boymurodov, G. K. Duisheeva, et al.

    THE AIM: To study heart and aortic involvement in patients with nephrotic syndrome (NS) depending on sex. PATIENTS AND METHODS. A retrospective analysis included 170 patients (mean age 32.1±12.0 years) with verified NS based on clinical and laboratory findings. All participants were divided into two subgroups: men (n=105) and women (n=65). Laboratory parameters, general clinical data, electrocardiographic (ECG), and echocardiographic parameters were assessed. RESULTS . In men with NS, the mean levels of diastolic and mean arterial pressure, platelet count, total cholesterol (TC), and creatinine were significantly higher, while total protein concentration was significantly lower compared to women. Women with NS had a statistically significantly higher heart rate, while hemoglobin (Hb), hematocrit, erythrocyte count, and mean corpuscular hemoglobin levels were significantly lower. Among all patients with NS, ECG signs of myocardial excitability and conduction disturbances were detected in 17.6 % and 4.1 % of cases, respectively. Left ventricular (LV) repolarization abnormalities were observed in 20 patients (11.7 %). Pathological ECG changes were found in 29 (27.6 %) men and 28 (43.0 %) women. Men had significantly larger linear dimensions of the LV, right ventricle, and aortic outflow tract compared to women. LV myocardial hypertrophy was detected in 17 (10 %) patients, while concentric LV remodeling was observed in 5 (2.9 %) cases. LV myocardial hypertrophy was more common in women. In men with NS, the LV myocardial mass index was significantly correlated with daily proteinuria (r=0.378; p=0.036), TC level (r=0.222; p=0.041), and fibrinogen concentration (r=0.306; p=0.021), while it was inversely correlated with albumin concentration (r=0.371; p=0.039). In women, the LV myocardial mass index showed a positive correlation with daily proteinuria (r=0.265; p=0.016) and fibrinogen concentration (r=0.230; p=0.019). CONCLUSION. Patients with NS frequently exhibit ECG signs of myocardial excitability and LV repolarization disturbances. Cardiac involvement in NS is primarily represented by concentric LV remodeling in men and eccentric LV myocardial hypertrophy in women. Regardless of sex, LV myocardial mass is strongly associated with daily proteinuria and fibrinogen concentration, while the diameter of the aortic outflow tract is linked to diastolic blood pressure levels.

  • Iron deficiency in patients with the chronic kidney disease: frequency and clinical-prognostic aspects

    by I.T. Murkamilov, K.A. Aitbaev, V.V. Fomin, Zh.A. Murkamilova, Z.R. Raimzhanov, Sh.SH. Khakimov, J.I. Solizhonov, T.F. Yusupova, F.A. Yusupov, K.A. Gassanov, et al.

    In recent years, a significant global rise in the prevalence of chronic kidney disease (CKD) and its associated cardiovascular complications (CVC) has been observed. The urgent need to slow the advancement of renal impairment and minimize the risk of cardiovascular complications (CVC) is critical, particularly in the context of managing metabolic disorders like iron deficiency (ID). Objective. Tho evaluate the prevalence of iron deficiency and its association with various risk factors contributing to the progression of renal dysfunction in individuals diagnosed with CKD. Materials and methods. This study included 1.309 patients with CKD, comprising 731 males and 578 females aged 16—78 years, with a mean age of 40.5±13.6 years. Comprehensive clinical and laboratory evaluations were conducted, including an assessment of the frequency of iron deficiency categorized by CKD stage and sex. Statistical analyses were performed utilizing Statistica 10.0 and Microsoft Excel. Results. Among the cohort, patients with a glomerular filtration rate (GFR) of ≥60 mL/min (Group 1) exhibited higher incidences of grade I obesity, elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and daily proteinuria, as well as decreased serum total protein levels. Conversely, patients with a GFR of <60 mL/min (Group 2) displayed older age, increased hemodynamic indices, higher erythrocyte sedimentation rate, elevated glucose and potassium levels, and reduced high-density lipoprotein cholesterol (HDL-C) and calcium concentrations. Serum iron levels were significantly different, measuring 17.0±7.1 µmol/L in Group 1 compared to 14.8±7.8 µmol/L in Group 2 (p<0.001). The prevalence of iron deficiency increased with the progression of CKD, from 8.7% at stage C1 to 28.7% at stage C5. Gender differences in iron deficiency prevalence were particularly pronounced at stages C3A (7.5% in males vs. 21.1% in females) and C5 (26.3% in males vs. 31.4% in females). Overall, iron deficiency was identified in 246 patients (26.8%): 116 males (15.8%) and 130 females (22.4%). Conclusion. The findings indicate that serum iron concentration decreases with the deterioration of renal filtration function in patients with CKD, particularly among females. The prevalence of iron deficiency increases with disease progression, peaking at the pre-dialysis stage. Furthermore, iron deficiency in CKD is closely associated with modifiable cardiovascular risk factors.

  • Left Ventricular Hypertrophy in Chronic Kidney Disease: Prevalence and Association With Renal Function Parameters

    by I. T. Murkamilov, K. A. Aitbaev, V. V. Fomin, Zh. A. Murkamilova, Z. R. Rayimzhanov, Sh. Sh. Khakimov, Zh. I. Solizhonov, Sh. E. Umurzakov, F. A. Yusupov, T. F. Yusupova, et al.

    Aim        To evaluate the prevalence of left ventricular hypertrophy (LVH) and its relationship with renal function parameters in patients with chronic kidney disease (CKD). Material and methods    This cross-sectional retrospective cohort study included 1,080 patients with pre-dialysis CKD. The mean age was 39.0±12.9 years (17-74 years; median, 38 [28-49 years]). Patients were divided into three groups: Group 1 (n=381; GFR ≥60 mL/min/1.73 m²), Group 2 (n=181; GFR 59-30 mL/min/1.73 m²), and Group 3 (n=518; GFR ≤29 mL/min/1.73 m²). All patients underwent clinical and laboratory evaluation and echocardiography. Statistical analysis was performed using STATISTICA 10.0, utilizing Student's t -test, Mann-Whitney U test, ANOVA, and Spearman's correlation. Differences were considered statistically significant at p Results The LV linear dimensions and mass index were significantly greater in patients with more pronounced renal impairment. Signs of LVH were identified in 489 patients (45.2%). The prevalence of LVH increased alongside the progression of CKD, reaching 8.8%, 26.5%, 35.5%, 35.1%, 52.7%, and 76.4% in stages C1-C5, respectively. Eccentric LVH was more prevalent than concentric LVH. LV mass index and relative wall thickness correlated significantly with both GFR and proteinuria levels. Conclusion         Patients with CKD exhibit a high prevalence of LVH, which rises as the GFR declines and peaks at the advanced stages of the disease. LVH is predominantly eccentric. There is a statistically significant relationship between LV remodeling parameters and renal function, specifically GFR and proteinuria.

  • Myocarditis: Clinical Variants and Prognosis

    by I. Murkamilov, K. Aitbaev, Z. Raimzhanov, Zh. Murkamilova, J. Solizhonov, K. Gassanov, O. Zakirov, Sh. Hakimov, D. Ymankulov, K. Khabibullaev, et al.

    Myocarditis is a focal or diffuse inflammatory lesion of the heart muscle that clinically manifests with symptoms and/or signs of heart failure (HF). It is caused by infectious agents (viruses, bacteria, parasites, protozoa) and non-infectious factors (toxins, poisons, heavy metals, burns, radiation, metabolic disorders, allergens, pesticides, medications), as well as systemic connective tissue diseases (CTDs). Clinically, myocarditis can present in fulminant, subacute, or chronic forms (active or persistent), and also as giant cell or eosinophilic myocarditis. The main pathogenetic mechanisms include the entry of pathogens through portals such as the respiratory tract, gastrointestinal tract, or genitourinary system; viral penetration into cardiomyocytes; viral replication; disruption of the multiprotein complex within the cell; activation of the inflammasome cascade; apoptosis, necrobiosis, and necrosis of cardiomyocytes; formation of inflammatory cellular infiltration; chemokine and cytokine production; and autoimmune damage to cardiomyocytes, leading to structural and functional remodeling of the heart. Diagnosis of myocarditis is based on anamnesis (acute onset, association with infection), clinical symptoms (dyspnea, palpitations, fever, chest pain), electrocardiographic findings (conduction and/or excitability disturbances), echocardiographic findings (reduced systolic function, chamber dilatation), laboratory tests (leukocytosis, lymphopenia, elevated ESR, increased levels of brain natriuretic peptide, C-reactive protein, fibrinogen, procalcitonin, ferritin, D-dimer, immunoglobulin E), and serological tests (identification of viruses, bacteria, etc.). Additional diagnostic tools include measurements of troponins, lactate dehydrogenase, CK-MB, interleukin-6 titers, myocardial autoantibodies, assessment of CTD activity, and viral load quantification via polymerase chain reaction (PCR). In cases of acute myocarditis, cardiac MRI with gadolinium shows subepicardial and transmural contrast enhancement. The gold standard for diagnosis remains endomyocardial biopsy with light microscopy of formalin-fixed paraffin-embedded sections, immunohistochemical analysis, molecular tests (PCR), and transmission electron microscopy. Modern treatment of myocarditis includes etiological and pathogenetic therapy. In the majority of patients, especially in milder cases, myocarditis resolves spontaneously without active intervention, with spontaneous recovery occurring as the infection subsides. Severe and extremely severe cases often progress to post-myocarditic cardiosclerosis, leading to dilated cardiomyopathy and the potential need for heart transplantation. This article presents the results of a clinical case of acute myocarditis in a 38-year-old patient with bilateral pneumonia. The diagnosis of acute myocarditis was established based on medical history, clinical presentation, echocardiographic findings, and laboratory and serological data.

  • Cardiovascular and cerebral complications during abdominoplasty and liposuction

    by I. T. Murkamilov, A. A. Kubanych, V. V. Fomin, D. S. Ymankulov, T. F. Yusupova, Z. F. Yusupova, Yu. A. Furkat

    Liposuction as a radical technique to combat localized fat deposits is becoming more and more widely used in clinical medicine. The present review study is devoted to the analysis of published data concerning the development of possible complications during abdominoplasty and liposuction surgeries. Particular attention is paid to the study of cardiovascular and cerebral complications, their frequency, clinical spectrum, as well as the peculiarities of management of such cases by representatives of different levels of medical care. Complications during the performance of these procedures are characterized by a wide spectrum, develop in different periods of time and in the majority of cases are resolved safely. However, in some cases they occur in the first day after the operation and can be dangerous for human health. Risk factors for complications of abdominoplasty and/or liposuction are reviewed, including such as the use of general anesthesia, duration of surgical intervention, use of highdose lidocaine, large liposuction volume, inter- and postoperative volume overload or hypohydration, difficult-to-control pain syndrome, multimodal anesthesia, frequent vomiting, and late patient activation, prior use of nonsteroidal anti-inflammatory drugs, smoking, long-term contraception, pelvic inflammatory disease, body mass index ≥ 40 kg/m2, benign prostatic hyperplasia in men, elevated levels of C-reactive protein, fibrinogen, total cholesterol, triglycerides, creatinine, eosinophils, and low blood albumin and lymphocyte counts. Our findings may serve as a basis for the development of effective prevention and risk management strategies in this field of plastic surgery.

  • Chronic low-grade inflammatory phenotype: clinical significance, causal factors and approaches to therapy

    by K. A. Aitbaev, I. T. Murkamilov, V. V. Fomin, I. U. Abdurakhmanov, T. F. Yusupova, F. A. Yusupov, Zh. I. Solizhonov, Y. R. Boimurodov, G. K. Duisheeva, Sh. Sh. Khakimov, et al.

    CLIP is a chronic, systemic and smoldering inflammatory condition clearly indicated by a 2–4-fold increase in serum levels of inflammatory mediators such as interleukin-6 and C-reactive protein. Many other cellular and molecular mediators of inflammation are also involved in the development of CLIP. CLIP typically occurs in older people, hence also known as aging inflammation, and is an integral part of the aging spectrum of the immune system. Causal factors may include: persistent viral infections such as chronic cytomegalovirus infection; cellular aging and the inability, in this regard, to eliminate degraded materials and waste products; dysbiosis and impaired intestinal permeability, obesity and others. A significant body of evidence suggests that CLIP is a powerful contributor to senility and many other adverse health chronic conditions associated with aging. Many inflammatory mediators and their regulatory mechanisms in CLIP can serve as potential targets for therapeutic intervention. However, the complexity of the inflammatory network should be taken into account when developing new interventional strategies for the treatment of CLIP and associated chronic conditions. Non-pharmacological interventions such as caloric restriction and exercise have beneficial effects on CLIP and its causative factors, which in turn can provide significant health benefits. Metformin and resveratrol have anti-inflammatory properties and, in this regard, may serve as promising therapeutic agents for the treatment of chronic low-grade inflammation and frailty.